India Precision Medicine Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

India’s precision medicine ecosystem is increasingly moving towards genomic reference data that reflects the country’s population diversity. The GenomeIndia project has completed whole-genome sequencing for more than 10,000 individuals, while its broader biobank contains over 20,000 samples from 83 populations. Research published in 2026 identified nearly 130 million genetic variants among 9,768 sequenced individuals, including around 44 million variants not previously reported in major global databases. These findings highlight the limitations of relying exclusively on genomic reference datasets developed from predominantly European populations. As India-specific genomic resources expand, pharmaceutical companies, diagnostic providers and research institutions are gaining a stronger foundation for developing disease-risk models, pharmacogenomic applications and targeted therapies suited to Indian populations.

Artificial intelligence is becoming increasingly integrated with genomics to interpret large volumes of genetic and clinical information. In February 2026, the Department of Biotechnology highlighted AI-driven gene sequencing as an important component of India’s transition towards personalised prescriptions and predictive medicine. The government also announced Bio-AI Mulankur hubs to integrate AI-based predictions, laboratory validation and data analytics across genomics diagnostics, biomolecular design and synthetic biology. By July 2026, the government reported that GenomeIndia data was being used with AI and machine-learning tools to support indigenous precision medicine applications. This convergence is encouraging investment in computational biology, genomic interpretation and AI-assisted diagnostics while creating demand for platforms capable of translating complex genomic datasets into clinically useful insights.

Cancer care is becoming a major application area for precision medicine in India as genomic profiling and biomarker testing become more integrated into clinical pathways. Government programmes include the DIAMOnDS initiative, which provides advanced molecular diagnostics to eligible lung and breast cancer patients through 25 centres. In parallel, India has established an AI-enabled medical imaging resource containing more than one million radiology images and 20,000 pathology images for developing precision oncology algorithms. Commercial providers are also expanding comprehensive genomic profiling capabilities for cancer patients. These developments are increasing the role of next-generation sequencing, molecular biomarkers, liquid biopsy and AI-supported pathology in treatment selection. The trend is gradually shifting oncology from broad treatment protocols towards molecularly informed diagnosis and therapy selection.

India’s precision medicine ecosystem is increasingly addressing rare and inherited disorders through genomic testing, newborn screening and targeted therapies. The government’s UMMID initiative has established NIDAN Kendras focused on prenatal testing, newborn screening and genetic counselling for families at risk of genetic disorders. GenomeIndia is also creating a population-specific reference dataset that can support research into disease-associated variants across diverse Indian communities. In June 2026, the government highlighted gene therapy and personalised therapies as emerging areas supported by India’s expanding genomic infrastructure. This is broadening precision medicine beyond oncology into rare diseases, inherited disorders and genetic counselling. Greater availability of genomic testing and counselling is expected to strengthen early diagnosis and improve identification of patients who may benefit from targeted interventions.

India is building a larger national infrastructure to convert genomic information into practical healthcare applications. GenomeIndia has archived whole-genome sequencing data for more than 10,000 individuals at the Indian Biological Data Centre, while the project has also established a biobank containing more than 20,000 biospecimens. The IBDC provides dedicated biological-data repositories and high-performance computing infrastructure for research. Government programmes are increasingly connecting these resources with universities, hospitals, research institutions, start-ups and industry through collaborative projects. This is creating an ecosystem in which population genomics, clinical datasets, AI and laboratory research can be combined to develop diagnostic tools and personalised therapies. The resulting infrastructure is particularly relevant for Indian-specific risk prediction, pharmacogenomics and translational precision healthcare.